Compare HLN & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | ARGX |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 51.1B |
| IPO Year | N/A | 2017 |
| Metric | HLN | ARGX |
|---|---|---|
| Price | $9.88 | $850.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | N/A | ★ $971.89 |
| AVG Volume (30 Days) | ★ 10.3M | 340.7K |
| Earning Date | 07-31-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ 41.64 | N/A |
| EPS | 0.23 | ★ 23.27 |
| Revenue | ★ $15,096,588,575.00 | $3,683,281,000.00 |
| Revenue This Year | $1.51 | $91.22 |
| Revenue Next Year | $4.67 | $36.36 |
| P/E Ratio | $42.93 | ★ $34.93 |
| Revenue Growth | N/A | ★ 92.98 |
| 52 Week Low | $8.71 | $510.06 |
| 52 Week High | $11.42 | $934.62 |
| Indicator | HLN | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 37.51 |
| Support Level | $9.68 | $827.52 |
| Resistance Level | $9.65 | $878.19 |
| Average True Range (ATR) | 0.15 | 17.90 |
| MACD | 0.02 | -9.73 |
| Stochastic Oscillator | 92.06 | 18.94 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.